Cancer Management and Research (Apr 2020)
Plasma Long Non-Coding RNA RP11-438N5.3 Level for Non-Small Cell Lung Cancer Diagnosis [Letter]
Abstract
Chun-Qiu Yang, 1 Guo-Ming Zhang 2 1Department of Laboratory Medicine, Taihe County People’s Hospital, Fuyang 236600, People’s Republic of China; 2Department of Laboratory Medicine, Shuyang People’s Hospital, Shuyang Hospital Affiliated to Xuzhou Medical University, Shuyang 223600, People’s Republic of ChinaCorrespondence: Guo-Ming ZhangDepartment of Laboratory Medicine, Shuyang People’s Hospital, The Affiliated Shuyang Hospital of Xuzhou Medical University, Shuyang 223600, People’s Republic of ChinaEmail [email protected] Chen et al 1 published an article entitled “Plasma Long Non-Coding RNA RP11-438N5.3 as a Novel Biomarker for Non-Small Cell Lung Cancer” in the Cancer Management and Research journal. To evaluate the diagnostic efficiency of Plasma level of RP11-438N5.3 for non-small-cell lung cancer (NCLC), the investigators enrolled 69 NCLC patients and 69 healthy controls in this study. Plasma level of RP11-438N5.3 was determined using quantitative reverse transcription PCR (qRT-PCR), and receiver operating characteristic (ROC) curve analysis was assessed to determine the diagnostic performance of Plasma level of RP11-438N5.3 level in NCLC. They found that Plasma level of RP11-438N5.3 level was significantly lower in NCLC patients than healthy controls and the area under ROC curve (AUC) is 0.814. Therefore, they concluded that the Plasma level of RP11-438N5.3 was a novel diagnostic biomarker for NCLC. View the original paper by Chen and colleagues
